BioCryst Pharmaceuticals Files Additional Proxy Materials
Ticker: BCRX · Form: DEFA14A · Filed: Apr 23, 2026 · CIK: 0000882796
Sentiment: neutral
Topics: proxy-filing, corporate-governance
Related Tickers: BCRX
TL;DR
BioCryst (BCRX) dropped more proxy docs, check 'em.
AI Summary
BioCryst Pharmaceuticals Inc. filed a Definitive Additional Materials (DEFA14A) on April 23, 2026. This filing contains additional soliciting materials related to their business. The company's mailing and business address is 4505 Emperor Boulevard, Suite 200, Durham, NC 27703.
Why It Matters
This filing indicates ongoing corporate communications and potential shareholder engagement activities for BioCryst Pharmaceuticals, which could impact investor decisions.
Risk Assessment
Risk Level: low — This filing is a standard proxy material submission and does not inherently present new financial or operational risks.
Key Players & Entities
- BIOCRYST PHARMACEUTICALS INC (company) — Filer
- 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 (company) — Mailing and Business Address
FAQ
What type of filing is this?
This is a DEFA14A filing, which signifies Definitive Additional Materials and Rule 14(a)(12) material.
When was this filing accepted by the SEC?
The filing was accepted on April 23, 2026.
What is BioCryst Pharmaceuticals' CIK number?
BioCryst Pharmaceuticals' CIK number is 0000882796.
What is the company's stated business address?
The business address is 4505 Emperor Boulevard, Suite 200, Durham, NC 27703.
What SIC code is associated with BioCryst Pharmaceuticals?
The SIC code is 2836, which pertains to Biological Products, (No Diagnostic Substances).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 23, 2026 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).